Remove 2019 Remove Communication Remove Labelling
article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. 2021;398(10300):583-598. 2022;327(6):534-545. doi:10.1001/jama.2022.0078 Obesity, sleep apnea, and hypertension. Hypertension.

article thumbnail

Pharmacist to Clinical Strategy Leader: Brendan Doran on Building a Career in Biotech

The Nontraditional Pharmacist

So, we would have spoken in 2019. And ultimately, it’s to ensure we get the data because the data are ultimately what turns into your FDA approved label and demonstrates what you need. So, good talking to you. Matt Paterini (01:21): No, we appreciate the time. And remember, COVID was in there too, right? It’s 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

There are too many drug approvals, label updates, and new data published for even the most skilled and experienced oncology pharmacist to keep up with, let alone those still building their baseline knowledge. December 12, 2019. Oncology pharmacy practice changes at a rapid pace. However, one person cannot do all these things well.

article thumbnail

To Combat Medication Errors, Proper Pharmacy Inventory Counts Are Essential

Pharmacy Times

Detect-A-Dose lid-label cover enhances medication recognition, reducing packaging errors through a contrasting visual pattern. 1-3 Detect-A-Dose Lid Label Covers. 4 Detect-A-Dose features a contrasting black and white pattern on the underside of its label to make missing doses for patients apparent to pharmacists. 2019:10(2).

article thumbnail

J&J eyes prostate cancer label expansion for Akeega

Pharmaceutical Technology

The hormone therapy, approved in 2019, is forecast to see annual sales of $5.3bn by 2031. Robert Barrie July 7, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The application comes hot on the heels of positive data for Akeega unveiled at this year’s American Society of Clinical Oncology (ASCO) conference.

article thumbnail

Sarepta and Roche halt DMD gene therapy’s use after second death  

Pharmaceutical Technology

By GlobalData Learn more about Strategic Intelligence Corwin added that Elevidys’s label will likely be updated to reflect the risk of ALF. Sarepta Therapeutics, who developed the therapy, holds US rights to the drug, while Roche gained rights to other global territories through a 2019 agreement. Sign up for our daily news round-up!

article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)